

Gemini Stock Analysis Report

Based on the detailed analysis report provided (dated January 3, 2026), here is the evaluation for **AUROPHARMA.NS**.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** 3-year daily candlestick charts.
 - **Trend Indicators:** Moving Averages (EMA 20, 50, 200), Supertrend, Golden Cross analysis.
 - **Momentum/Volatility:** RSI, MACD, Bollinger Bands, Volatility Squeeze.
 - **Relative Strength:** Comparative analysis vs. CNXPHARMA (Sector).
 - **Fundamentals:** 4-year long-term view and 6-quarter short-term view.
 - **Analyst Estimates:** Consensus target prices and ratings.
- **Data Missing:**
 - **Weekly/Monthly Charts:** While the daily chart covers 3 years, a dedicated weekly timeframe chart would clarify the major structural resistance levels more cleanly.
 - **Volume Profile:** Standard volume bars are present, but Volume Profile (VPVR) is missing to identify high-volume nodes for support/resistance.
- **Confidence Level: High.** The report provides a comprehensive technical and fundamental overview sufficient for a positional trade decision. *Note: The report date is Jan 2026; the analysis assumes this is the current trading date (\$T_0\$).*

Step 2: Analyze the Setup

- **Trend Structure (Bullish):** The stock is in a confirmed uptrend. It is trading above its 20, 50, and 200-day EMAs. A **Golden Cross** (50 EMA crossing above 200 EMA) occurred in late November 2025, which is a significant intermediate-term bullish signal.
- **Support Strength:** The price (1215.40) is holding comfortably above the EMA 20 (1199.75) and the Supertrend Support (1158.19). The "Cloud" of EMAs (1160-1200) provides a strong floor.
- **Relative Strength (Turnaround):** While classified as a "Weakening Leader" due to 1-year lagging performance (RS 0.908), the short-term momentum is shifting. The 3-month RS (1.046) and 1-month RS (1.010) are in "Leader" territory, indicating the stock is currently outperforming its sector.
- **Momentum (Mixed):**
 - **RSI (56.42):** In a bullish zone (40-60 range), not overbought, allowing room for upside.
 - **MACD:** Currently flagged as "**Bearish**" with weakening momentum (histogram is negative). This suggests the stock is in a short-term consolidation or pullback phase within the larger uptrend.
- **Fundamentals:** Long-term growth is evident, though recent quarters show a contraction in Revenue (-7.03%) and Net Income (-8.71%). The trade relies on technical momentum and the market pricing in a recovery.

Step 3: Formulate the Recommendation

Verdict: YES.

The technical structure supports a long position. The "Golden Cross" alignment combined with improving short-term relative strength suggests the stock is emerging from a consolidation base. The current consolidation (indicated by the soft MACD) offers a reasonable entry point before the next leg up.

- **Entry Price: INR 1215 - INR 1220** (Current Market Price).
 - *Rationale:* Entering near the EMA 20 provides a good risk-reward ratio.
- **Stop Loss: INR 1150** (Closing Basis).

Gemini Stock Analysis Report

- **Rationale:** This places the stop below the Supertrend support (1158) and the critical 200-day EMA (1161). A close below this level invalidates the intermediate uptrend. (Risk: ~5.4%).
- **Take Profit: INR 1320.**
- **Rationale:** This targets the resistance zone seen in mid-2025 and aligns slightly above the analyst consensus target of INR 1298. (Reward: ~8.6%).

Risk/Reward Ratio: ~1.6 (Acceptable for this probability).

Disclaimer: This analysis is based on the simulated future date (2026) provided in the PDF charts. Ensure these parameters align with your actual trading system's date.

News & Analyst Targets

Based on the latest market data and news for the week ending **January 3, 2026**, here is the research update on **Aurobindo Pharma (AUROPHARMA)**.

1) Latest News for AUROPHARMA (Week of Dec 29, 2025 - Jan 3, 2026)

Acquisition of Khandelwal Laboratories' Business (Key Highlight):

- On **January 1, 2026**, Aurobindo Pharma's wholly-owned subsidiary, **Auro Pharma Ltd**, completed the acquisition of the domestic branded non-oncology prescription formulation business of **Khandelwal Laboratories**.
- **Deal Value:** The transaction was an all-cash deal valued at **INR 325 Crore** (approx. \$36 million).
- **Impact:** The acquisition adds **23 brands** (primarily in **pain management** and **anti-infectives**) and a field force of ~470 personnel to Aurobindo's domestic portfolio. It is expected to strengthen their presence in the Indian branded formulations market.
- **Stock Reaction:** Shares of Aurobindo Pharma reacted positively, trading up ~1.5% to the **INR 1,210-INR 1,212** levels on January 2 following the news.

Strategic Stake Increase in JV:

- Late in the previous week (late Dec 2025), the company announced that its subsidiary, **Helix Healthcare BV**, would acquire an additional **20% stake** in its joint venture, **Luoxin Aurovitas**, solidifying its control.

Solar Power Investment Update:

- On **December 29, 2025**, the company informed exchanges of a revised timeline for its solar power initiatives, extending the completion of stake acquisitions to March 2026.

2) Brokerage Upgrades & Downgrades

- **Recent Activity:** The most significant recent rating action came from **PhillipCapital** in late December 2025, maintaining a bullish stance. Conversely, earlier in the fiscal year (July 2025), **Macquarie** had issued a "Double Downgrade" to *Underperform*, citing US generic market pressures, but domestic brokerage sentiment has remained largely constructive recently.
- **Consensus View:** The analyst community remains moderately positive ("Buy" consensus), driven by the stable US generic pipeline and increasing focus on the domestic branded market (e.g., the Khandelwal Labs deal).

Gemini Stock Analysis Report

3) Other News Impacting AUROPHARMA

Regulatory Updates (USFDA):

- **Unit-IV (Andhra Pradesh):** In mid-December 2025, the USFDA issued a **Form 483 with 5 observations** following an inspection. The company has stated these are procedural in nature and does not anticipate a material financial impact.
- **Unit-XII & Eugia Unit-II:** Recent months (Sept-Nov 2025) saw inspections at these units resulting in 8 and 9 observations respectively. The market is closely watching for the final classification (VAI/OAI) of these inspections.
- **Unit-I (Apitoria):** A positive development occurred in November 2025 when the USFDA classified the facility as **VAI (Voluntary Action Indicated)**, effectively clearing the regulatory cloud over this specific API unit.

Biosimilar Portfolio Changes:

- On **December 26, 2025**, subsidiary **CuraTeQ Biologics** mutually terminated its license agreement with BioFactura Inc. for the *Ustekinumab* biosimilar, citing strategic prioritization of its portfolio.

4) Latest Analyst Targets & Ratings

Below is a summary of the latest available targets from major brokerages as of early **January 2026**.

Brokerage Firm	Rating	Price Target (INR)	Date of Report	Sentiment
PhillipCapital	Buy	1,450	Dec 24, 2025	Bullish
CLSA	Buy	1,340	Nov 06, 2025	Bullish
HSBC	Buy	1,300	Oct 13, 2025	Positive
Axis Capital	Buy	1,260	Nov 06, 2025	Moderate Buy
Kotak Inst. Equities	Sell	1,115	Nov 06, 2025	Bearish
Macquarie	Underperform	1,010	Jul 08, 2025	Negative
Consensus Average	Buy	~1,298	Jan 03, 2026	Moderate Buy

Analyst Note: The stock is currently trading near **INR 1,210**. The acquisition of Khandelwal Labs is viewed as a long-term positive for margin expansion in the domestic market, though USFDA compliance remains the key short-term risk factor to watch.

Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1215.40

Generated: 2026-01-03 12:46

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	50.4/100
:	

== RS RATIOS ==:

1M RS:	1.010 [Leader]
3M RS:	1.046 [Leader]
6M RS:	1.017 [Leader]
1Y RS:	0.908 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.908 (≤ 1.0)
✓ Performance Improving:	3M (+11.9%) > 6M (+5.0%)

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1199.75
EMA 50:	1182.56
EMA 200:	1161.85
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-27 00:00:00
Golden Cross Price:	1235.80


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

Current Price:	1215.40
Upper Band:	1234.03
Middle Band (SMA 20):	1196.41
Lower Band:	1158.79
%B:	0.7524
Band Width:	0.0629
Status:	Upper Half
Signal:	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1158.19
Signal Identified On:	2025-09-11


Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	3.40
Signal Line:	4.98
Histogram:	-1.58
Trend:	Bearish
Momentum:	Weakening
Signal:	None

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0629
ATR:	23.0571
Total Signals:	41
Signal 1:	BB Squeeze + ATR Contraction at 2025-12-29 00:00:00 (Price: 123.00)
Signal 2:	BB Squeeze + ATR Contraction at 2025-12-30 00:00:00 (Price: 118.00)
Signal 3:	BB Squeeze + ATR Contraction at 2025-12-31 00:00:00 (Price: 118.00)
Signal 4:	BB Squeeze + ATR Contraction at 2026-01-01 00:00:00 (Price: 119.00)
Signal 5:	BB Squeeze + ATR Contraction at 2026-01-02 00:00:00 (Price: 123.00)

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	56.42
Current Volume:	516055
Volume MA 20:	686412
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-02-03 00:00:00, Price: 1125.40
Bearish Div 1:	Date: 2024-08-30 00:00:00, Price: 1569.40
Bearish Div 2:	Date: 2025-10-13 00:00:00, Price: 1136.80

AUROPHARMA.NS RSI-Volume Divergence Analysis



Aurobindo Pharma Ltd. ^①

Aurobindo Pharma Live Share Price Today, Share Analysis and Chart

ABOUT Founded in 1986, Aurobindo Pharma is a global pharmaceutical company headquartered in Hyderabad, India. It develops, manufactures, and markets generic and branded specialty pharmaceuticals, along with active pharmaceutical ingredients, across 150+ co.. [Read More](#)

 Watchlist
  Portfolio
  Alert
  My Notes

[See details](#)

Aurobindo Pharma Key Metrics

- DVM
- Key Metrics
- Price Chart
- Forecaster
- Financials
- Technicals
- Shareholding
- Deals
- Documents
- Corporate actions
- Company Profile

Trendlyne Snapshot - AUROPHARMA_forecaster

MarketsSTARFOLIOAlertsF&OMFReportsScreenersSubscribeSuperstarsPortfolioWatchlistInsider TradesResultsData DownloaderMore

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

In 2 Starfolio Baskets

1215.4022.40 (1.88%)

533.1K NSE+BSE Volume
NSE 02 Jan, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Acquisition

Aurobindo Pharma's arm to buy non-oncology formulations segment of Khandelwal Labs for Rs 325 crore

See details

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1298, revenue growth forecast of 4.8%, and profit growth estimate of 4.6% for FY26, based on top 28 analyst calls.

Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)

SHARE PRICE TARGET FORECAST

12 MONTH ESTIMATE

LOW ESTIMATE: 730, HIGH ESTIMATE: 1640, CURRENT PRICE: 1215.4, AVG. ESTIMATE: 1298.4

EPS FORECAST

QUARTERANNUAL

ACTUAL EPS, AVG. ESTIMATE

CONSENSUS RECOMMENDATION

28 ANALYST Recommendations

BUY

RECOMMENDATION	STRONG BUY	BUY	SELL	STRONG SELL	DATE
18	5	1	4		Aug '25
18	5	2	3		Sep '25
18	5	2	3		Oct '25
18	5	2	3		Nov '25
18	5	2	3		Dec '25
18	5	2	3		Jan '26

● STRONG BUY ● BUY ● SELL ● STRONG SELL